Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer
Repp, R, van Ojik, H H, Valerius, T, Groenewegen, G, Wieland, G, Oetzel, C, Stockmeyer, B, Becker, W, Eisenhut, M, Steininger, HVolume:
89
Année:
2003
Langue:
english
Pages:
10
DOI:
10.1038/sj.bjc.6601367
Fichier:
PDF, 197 KB
english, 2003
File converter
Plus de résultats de recherche
More benefits 
